Maxim analyst Jason McCarthy downgraded Cero Therapeutics (CERO) to Hold from Buy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Why Is CERo Therapeutics Stock Down 80% Today?
- CERo Therapeutics Faces Nasdaq Delisting Suspension
- Cero Therapeutics discloses Nasdaq Panel listing determination
- Cero Therapeutics’ Innovative AML Treatment Study: A Potential Game-Changer?